Functionalized nanospheres for targeted delivery of paclitaxel

Journal of Controlled Release

Volumn 171, Issue 3, 2013, Pages 315-321

  Bushman, Jared ^a   Vaughan, Asa ^a   Sheihet, Larisa ^a   Zhang, Zheng ^a   Costache, Marius ^a   Kohn, Joachim ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Biotinylation; Breast cancer; Nanosphere; Paclitaxel; Pretargeted radioimmunotherapy; Targeting

Indexed keywords

AMINO ACIDS; ANTIBODIES; CELL CULTURE; CELL PROLIFERATION; CELLS; CYTOLOGY; DISEASES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; PROTEINS; RADIOTHERAPY;

BIOTINYLATIONS; BREAST CANCER; PACLITAXEL; RADIOIMMUNOTHERAPY; TARGETING;

NANOSPHERES;

HERMES ANTIGEN; MACROGOL; NANOSPHERE; OLIGOMER; PACLITAXEL;

ARTICLE; BIOTINYLATION; BREAST CARCINOMA; CANCER CELL; CELL LINE; CELL POPULATION; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; HUMAN CELL; HYDRODYNAMICS; IC 50; IMMUNOREACTIVITY; IN VITRO STUDY; NANOENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

4-DIMETHYLAMINOPYRIDINIUM-P-TOLUENE SULFATE; ANTI-CD44 ANTIBODY; BIOTINYLATED TYROSINE-DERIVED NANOSPHERES; BIOTINYLATED TYROSINE-DERIVED NANOSPHERES LOADED WITH PACLITAXEL; BIOTINYLATION; BREAST CANCER; BTYR-NSP; BTYR-NSP-PTX; CETYLTRIMETHYLAMMONIUM BROMIDE; CTAB; DCC; DESAMINOTYROSYL TYROSINE OCTYL ESTER; DIISOPROPYLCARBODIIMIDE; DIMETHYLFORMAMIDE; DIPC; DISSOCIATION CONSTANT; DMF; DPTS; DTO; ENHANCED PERMEABILITY AND RETENTION; EPITHELIAL-SPECIFIC ANTIGEN; EPR; ESA; GEL PERMEATION CHROMATOGRAPHY; GPC; HOBT; HYDROXYBENZOTRIAZOLE; KD; N,N′-DICYCLOHEXYLCARBODIIMIDE; N-HYDROXYSUCCINIMIDE; NANOSPHERE; NHS; NMR; NUCLEAR MAGNETIC RESONANCE; OLIGO(DTO-SA); OLIGOMERS OF DESAMINOTYROSYL TYROSINE OCTYL ESTER AND SUBERIC ACID; PACLITAXEL; PBS; PEG; PHOSPHATE BUFFERED SALINE; POLY(ETHYLENE GLYCOL); PRETARGETED RADIOIMMUNOTHERAPY; PTX; SA; STA; STREPTAVIDIN; SUBERIC ACID; TARGETING; TETRAHYDROFURAN; THF; TYR-NSP; TYR-NSP-PTX; TYROSINE DERIVED NANOSPHERES LOADED WITH PACLITAXEL; TYROSINE-DERIVED NANOSPHERES; ΑCD44;

ANTIBODIES, IMMOBILIZED; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOTINYLATION; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; NANOSPHERES; PACLITAXEL; POLYETHYLENE GLYCOLS; STREPTAVIDIN;

EID: 84892906904     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.06.017     Document Type: Article

References (48)

1. E. Cukierman, D.R. Khan, The benefits and challenges associatedwith the use of drug delivery systems in cancer therapy, Biochem. Pharmacol. 80 (2010) 762-770.
2. Y. Matsumura, K. Kataoka, Preclinical and clinical studies of anticancer agent-incorporating polymer micelles, Cancer Sci. 100 (2009) 572-579.
3. V.P. Torchilin, Structure and design of polymeric surfactant-based drug delivery systems, J. Control. Release 73 (2001) 137-172. (Pubitemid 32544594)
4. R. Haag, F. Kratz, Polymer therapeutics: concepts and applications, Angew. Chem. Int. Ed. 45 (2006) 1198-1215. (Pubitemid 44097641)
5. R. Gref, Y. Minamitake, M. Peracchia, V. Trubetskoy, V. Torchilin, R. Langer, Biodegradable long-circulating polymeric nanospheres, Science 263 (1994) 1600-1603. (Pubitemid 24128361)
6. B.A. Pfeifer, J.A. Burdick, R. Langer, Formulation and surface modification of poly(ester-anhydride) micro- and nanospheres, Biomaterials 26 (2005) 117-124. (Pubitemid 38789094)
7. S.M. Moghimi, A.C. Hunter, J.C. Murray, Long-circulating and target-specific nanoparticles: theory to practice, Pharmacol. Rev. 53 (2001) 283-318. (Pubitemid 32476118)
8. Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res. 46 (1986) 6387-6392. (Pubitemid 17221789)
9. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, R. Langer, Nanocarriers as an emerging platform for cancer therapy, Nat. Nanotechnol 2 (2007) 751-760. (Pubitemid 350223348)
10. F.X. Gu, R. Karnik, A.Z. Wang, F. Alexis, E. Levy-Nissenbaum, S. Hong, R.S. Langer, O.C. Farokhzad, Targeted nanoparticles for cancer therapy, Nano Today 2 (2007) 14-21. (Pubitemid 46672835)
11. P.K. Gupta, Kapil, Amit Goyal, Neeraj Mishra, Suresh Vyas, Suresh, M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B, J. Drug Target. 15 (2007) 701-713. (Pubitemid 350201323)
12. F. Gu, L. Zhang, B.A. Teply, N. Mann, A. Wang, A.F. Radovic-Moreno, R. Langer, O.C. Farokhzad, Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers, Proc. Natl. Acad. Sci. 105 (2008) 2586-2591. (Pubitemid 351520557)
13. D. Kim, E.S. Lee, K.T. Oh, Z.G. Gao, Y.H. Bae, Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH, Small 4 (2008) 2043-2050.
14. Z. Shen, Y. Li, K. Kohama, B. Oneill, J. Bi, Improved drug targeting of cancer cells by utilizing actively targetable folic acid-conjugated albumin nanospheres, Pharmacol. Res. 63 (2011) 51-58.
15. X.-B. Xiong, A. Mahmud, H. Uludaǧ, A. Lavasanifar, Multifunctional polymeric micelles for enhanced intracellular delivery of doxorubicin to metastatic cancer cells, Pharm. Res. 25 (2008) 2555-2566.
16. R.F. Meredith, D.J. Buchsbaum, Pretargeted radioimmunotherapy, Int. J. Radiat. Oncol. Biol. Phys. 66 (2006) S57-S59. (Pubitemid 44353955)
17. P.S. Stayton, S. Freitag, L.A. Klumb, A. Chilkoti, V. Chu, J.E. Penzotti, R. To, D. Hyre, I. Le Trong, T.P. Lybrand, R.E. Stenkamp, Streptavidin-biotin binding energetics, Biomol. Eng. 16 (1999) 39-44. (Pubitemid 30184837)
18. P.L. Weiden, H.B. Breitz, Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL), Crit. Rev. Oncol. Hematol. 40 (2001) 37-51. (Pubitemid 32923069)
19. P.L. Weiden, H.B. Breitz, O. Press, J.W. Appelbaum, J.K. Bryan, S. Gaffigan, D. Stone, D. Axworthy, D. Fisher, J. Reno, Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results, Cancer Biother. Radiopharm. 15 (2000) 15-29. (Pubitemid 30108614)
20. H.B. Breitz, P.L. Weiden, P.L. Beaumier, D.B. Axworthy, C. Seiler, F.M. Su, S. Graves, K. Bryan, J.M. Reno, Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin, J. Nucl. Med. 41 (2000) 131-140. (Pubitemid 30046695)
21. A. Forero, P.L. Weiden, J.M. Vose, S.J. Knox, A.F. LoBuglio, J. Hankins, M.L. Goris, V.J. Picozzi, D.B. Axworthy, H.B. Breitz, R.B. Sims, R.G. Ghalie, S. Shen, R.F. Meredith, Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma, Blood 104 (2004) 227-236. (Pubitemid 38879862)
22. A. Forero-Torres, S. Shen, H. Breitz, R.B. Sims, D.B. Axworthy, M.B. Khazaeli, K.H. Chen, I. Percent, S. Besh, A.F. LoBuglio, R.F. Meredith, Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein, Cancer Biother. Radiopharm. 20 (2005) 379-390. (Pubitemid 41216102)
23. S. Shen, A. Forero, A.F. LoBuglio, H. Breitz, M.B. Khazaeli, D.R. Fisher, W. Wang, R.F. Meredith, Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies, J. Nucl. Med. 46 (2005) 642-651. (Pubitemid 41716409)
24. P.Y. Salaun, L. Campion, C. Bournaud, A. Faivre-Chauvet, J.P. Vuillez, D. Taieb, C. Ansquer, C. Rousseau, F. Borson-Chazot, S. Bardet, A. Oudoux, B. Cariou, E. Mirallie, C.H. Chang, R.M. Sharkey, D.M. Goldenberg, J.F. Chatal, J. Barbet, F. Kraeber-Bodere, Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement, J. Nucl. Med. 53 (2012) 1185-1192.
25. F. Kraeber-Bodere, P.Y. Salaun, C. Ansquer, D. Drui, E. Mirallie, A. Faivre-Chauvet, J. Barbet, D.M. Goldenberg, J.F. Chatal, Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC), Tumour Biol. 33 (2012) 601-606.
26. C. Nardin, D. Bolikal, J. Kohn, Nontoxic block copolymer nanospheres: design and characterization, Langmuir 20 (2004) 11721-11725. (Pubitemid 40049647)
27. A.D. Costache, L. Sheihet, K. Zaveri, D.D. Knight, J. Kohn, Polymer-drug interactions in tyrosine-derived triblock copolymer nanospheres: a computational modeling approach, Mol. Pharm. 6 (2009) 1620-1627.
28. L. Sheihet, R.A. Dubin, D. Devore, J. Kohn, Hydrophobic drug delivery by self-assembling triblock copolymer-derived nanospheres, Biomacromolecules 6 (2005) 2726-2731. (Pubitemid 41388286)
29. L. Sheihet, P. Chandra, P. Batheja, D. Devore, J. Kohn, B. Michniak, Tyrosine-derived nanospheres for enhanced topical skin penetration, Int. J. Pharm. 350 (2008) 312-319.
30. B.E. Kilfoyle, L. Sheihet, Z. Zhang, M. Laohoo, J. Kohn, B.B. Michniak-Kohn, Development of paclitaxel-TyroSpheres for topical skin treatment, J. Control. Release 163 (2012) 18-24.
31. L. Sheihet, O.B. Garbuzenko, J. Bushman, M.K. Gounder, T. Minko, J. Kohn, Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor, Eur. J. Pharm. Sci. 45 (2012) 320-329.
32. L. Sheihet, K. Piotrowska, R.A. Dubin, J. Kohn, D. Devore, Effect of tyrosine-derived triblock copolymer compositions on nanosphere self-assembly and drug delivery, Biomacromolecules 8 (2007) 998-1003. (Pubitemid 46488484)
33. D.E. McCloskey, S.H. Kaufmann, L.J. Prestigiacomo, N.E. Davidson, Paclitaxel induces programmed cell death in MDA-MB-468 human breast cancer cells, Clin. Cancer Res. 2 (1996) 847-854. (Pubitemid 26168937)
34. C. Fillmore, C. Kuperwasser, Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy, 2008. R25.
35. F. Forozan, R. Veldman, C.A. Ammerman, N.Z. Parsa, A. Kallioniemi, O.P. Kallioniemi, S.P. Ethier, Molecular cytogenetic analysis of 11 new breast cancer cell lines, Br. J. Cancer 81 (1999) 1328-1334.
36. J.A. Magee, E. Piskounova, S.J. Morrison, Cancer stem cells: impact, heterogeneity, and uncertainty, Cancer Cell 21 (2012) 283-296.
37. R. Singh, J.W. Lillard Jr., Nanoparticle-based targeted drug delivery, Exp. Mol. Pathol. 86 (2009) 215-223.
38. M. Pulkkinen, J. Pikkarainen, T. Wirth, T. Tarvainen, V. Haapa-aho, H. Korhonen, J. Seppala, K. Jarvinen, Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity, Eur. J. Pharm. Biopharm. 70 (2008) 66-74.
39. S.I. Thamake, S.L. Raut, A.P. Ranjan, Z. Gryczynski, J.K. Vishwanatha, Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homobifunctional spacer for active targeting in cancer therapy, Nanotechnology 22 (2011) 035101.
40. F. Fay, C.J. Scott, Antibody-targeted nanoparticles for cancer therapy, Immunotherapy 3 (2011) 381-394.
41. N. Kamaly, G. Fredman, M. Subramanian, S. Gadde, A. Pesic, L. Cheung, Z.A. Fayad, R. Langer, I. Tabas, O.C. Farokhzad, Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles, Proc. Natl. Acad. Sci. U. S. A. 110 (2013) 6506-6511.
42. O.C. Farokhzad, S. Jon, A. Khademhosseini, T.N. Tran, D.A. Lavan, R. Langer, Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells, Cancer Res. 64 (2004) 7668-7672. (Pubitemid 39446893)
43. L. Borsi, E. Balza, M. Bestagno, P. Castellani, B. Carnemolla, A. Biro, A. Leprini, J. Sepulveda, O. Burrone, D. Neri, L. Zardi, Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin, Int. J. Cancer (Journal international du cancer), 102 (2002) 75-85.
44. M.K. Yu, J. Park, S. Jon, Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy, Theranostics 2 (2012) 3-44.
45. T. Lammers, F. Kiessling, W.E. Hennink, G. Storm, Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress, J. Control. Release 161 (2012) 175-187.
46. T. Igawa, H. Tsunoda, T. Kuramochi, Z. Sampei, S. Ishii, K. Hattori, Engineering the variable region of therapeutic IgG antibodies, MAbs 3 (2011) 243-252.
47. A. Azimzadeh, M.H. Van Regenmortel, Antibody affinity measurements, J. Mol. Recognit. 3 (1990) 108-116.
48. B. Li, L. Zhao, H. Guo, C. Wang, X. Zhang, L. Wu, L. Chen, Q. Tong, W. Qian, H. Wang, Y. Guo, Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma, Blood 114 (2009) 5007-5015. Bioengineering